Phase 1 Hepatitis B Trial, Recruiting NCT07342881 Sponsor: Aligos Therapeutics Condition: Hepatitis B
Back to Hepatitis B

Phase 1 Hepatitis B Trial, Recruiting

NCT07342881
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman between 18 and 75 years old
  • Your body mass index (a measure of body weight relative to height) is between 17.5 and 40.0, and you weigh more than 50 kg (110 lbs)
  • If you are a woman who could become pregnant, you and any male partner who has not had a vasectomy must agree to use highly effective birth control during the trial

If you have normal kidney function, you must also:

  • Be in good general health with no significant issues found during medical history review, vital signs, blood tests, or heart tracing (ECG)
  • Match certain characteristics (such as age, weight, and where possible, sex) to other participants in the study
  • Have normal kidney function, with no known or suspected kidney problems (confirm with trial site for specific test values)

If you have reduced kidney function, you must also:

  • Have a kidney function test result that confirms a certain level of kidney impairment, taken within 28 days before receiving the study drug
  • Have any form of kidney impairment, except for a current active condition called acute nephritic syndrome (a past history of this condition that is now in remission may still be acceptable)
  • Have been on stable medications to manage your health conditions for at least 28 days before your screening visit
  • Have a heart tracing (ECG) and vital signs that meet the study's requirements

Who may not be able to join:

  • You have a current or past illness that the study doctor believes could affect the results or put you at additional risk
  • You have a history of heart rhythm problems, certain risk factors for a specific heart condition called Torsade de Pointes (such as low potassium levels or a family history of long QT syndrome), or significant/unstable heart disease (confirm with trial site)
  • You have a history of a serious allergic reaction to a medication
  • You have used recreational drugs or have a history of drug misuse within the past year
  • You regularly drink more than 14 units of alcohol per week (if you are a woman) or more than 21 units per week (if you are a man)
  • You are unwilling to avoid alcohol for 48 hours before the study starts through to the end of the follow-up period
  • You have Hepatitis A, B, C, or E, HIV, or a current active infection such as COVID-19
  • Your liver enzyme levels (specific blood test results) are more than twice the normal upper limit (confirm with trial site)
  • Your bilirubin levels (a substance measured in blood) are more than 1.5 times the normal upper limit, unless a harmless condition called Gilbert's syndrome is suspected
  • You are pregnant or have a positive pregnancy test at enrolment

If you have normal kidney function, you may also not be able to join if:

  • Your haemoglobin (a measure of red blood cells) is below 10 g/dL

If you have reduced kidney function, you may also not be able to join if:

  • You are currently receiving haemodialysis or peritoneal dialysis (kidney filtering treatments)
  • Your haemoglobin is below 9 g/dL

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (800) 466-6059

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Aligos Therapeutics
Registry
ClinicalTrials.gov
Start date
20 February 2026
Est. completion
15 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Area under the concentration time curve [AUC]; Maximum plasma concentration [Cmax]; Minimum plasma concentration [Cmin]; C0 [predose]; Half-life [t1/2]; Time to maximum plasma concentration [Tmax]; Apparent Clearance (CL/F); Apparent Volume of Distribution (V/F); Total Amount of Drug Excreted in Urine (Ae); Renal Clearance (CLr)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov